Table 1. MPNST development in Nf1 mutant mice following p53 knockdown.

Mouse genotype (injection)	Hyperplasia	MPNST	MPNST latency, mean days (range)
Periostin-Cre; Nf1flox/flox (vehicle)	2/11	0/11	No tumors: 83-304d*
Periostin-Cre; Nf1flox/flox (pTomo-shNf1;shp53)	8/18	10/18	183d (144-278d)
GFAP-Cre; Nf1flox/null (vehicle)	2/6	0/6	No tumors: 49-217d*
GFAP-Cre; Nf1flox/null (pTomo-shNf1;shp53)	3/11	8/11	91d (25-211d)
GFAP-Cre; Nf1flox/flox (vehicle)	0/4	0/4	No tumors:129-153d*
GFAP-Cre; Nf1flox/flox (pTomo-shNf1;shp53)	2/5	3/5	176d (117-298d)
Wild-type (pTomo-shNf1;shp53)	0/4	0/4	No tumors: 182-365d#
Nf1+/− (pTomo-shNf1;shp53)	0/4	0/4	No tumors: 182-365d#

^*

Vehicle mice were euthanized and analyzed at time points equivalent to those when p53 shRNA-injected mice were euthanized or at a time when they became ill due to non-tumor-related issues (rectal prolapse or hydrocephalus). The details are provided below:

• Vehicle-injected GFAP-Cre; Nf1^flox/null mice: 2 mice at 49 days, 2 mice at 154 days and 2 mice at 217 days.
• Vehicle-injected Periostin-Cre; Nf1^flox/flox mice: 1 mouse at 83 days, 3 mice at 144 days, 2 mice at 154 days, 2 mice at 230 days, 2 mice at 259 days, and 1 mouse at 304 days.
• Vehicle-injected GFAP-Cre; Nf1^flox/flox mice: 2 mice at 129 days, 1 mouse at 138 days, and 1 mouse at 158 days.
• Wild-type and Nf1+/− mice: 2 mice at 183 days and 2 mice at 365 days for each group.

^#Wild-type and Nf1+/− mice were euthanized and analyzed at 6 month or 12 month time points, as no mice developed symptoms or non-tumor-related issues.